Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
Expects $272 Million In IPO Planned Wednesday
1/29/2010 6:52:32 AM
NEW YORK (AP) -- Ironwood Pharmaceuticals Inc. plans on raising about $272.4 million through an initial public offering and said it will use the proceeds to develop a drug for irritable bowel syndrome.
Sets IPO Price at $14-$16 Per Share to Raise Between $233 Million and $267 Million
JSC Human Stem Cell Institute
Announces IPO Price Range for Initial Public Offering
Files Registration Statement for Initial Public Offering
Medidata Solutions, Inc.
Prices Initial Public Offering
Astellas Pharma Inc.
) Buys Rights to New IBS Drug from
Will Pay $75 Million Upfront
(CRN) Files $75 Million Shelf Registration Statement
Forest Laboratories, Inc.
) Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation; Top-line Results Show Each Trial Met Primary and All Secondary Endpoints
Withdraws Its Registration Statement for Initial Public Offering
As Chief Commercial Officer and Senior Vice President of Marketing and Sales
(EPCT) Announces Pricing of Public Offering
comments powered by Disqus.
comments powered by
Biotech/Pharma - IPO, Updates